ESMO 2023

Highlights in eBC

DATO-DX - where is it going?

Preoperative checkpointinihition in ER+ disease

5 year follow-up

My highlights of ESMO23 in metastatic breast cancer

When the history of ADC is written: Redefining…

Lu-PSMA leads forward

The FGFR story in bladder cancer at ESMO23

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

ALINA - immediate change of practice!

Perioperativ immunotherapy for all resectable stage…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Tarlatamab in SCLC

My highlights from ESMO 2023

What was the most exciting news at ESMO23?

Anticipated updates and exciting new data for…

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

New and better biomarkers are needed!

5 year follow-up

Analysis of tumour microenvironment and…

Preoperative checkpointinihition in ER+ disease

Negative EFS results from NeoTrip

Neoadjuvant IO - is their new strategy in HR+ breast…

New data on neoadjuvant immunotherapy

Pembrolizumab solidifies as SOC in early-stage TNBC

My highlights of ESMO23 in early breast cancer

Prognostic score in early HR+/HER2-BC: translational…

HR+ study with > 20 % PCR

Use of immunotherapy in the perioperative setting of…

Clinically relevant effect of pembro also in PCR

Carry-over effects in monarchE confirmed

MonarchE - trial update

ER-low corresponds diagnostically to ER-0 breast cancer

Consolidation of data in early HR+ and triple-negative…

Detailed view of nodal-negative patients

Immunoncology in eBC - triple negative and more?

Metabolomics reveal differential expression of OMEGA 3…

Our guidelines are correct

Highlights in eBC

Studio NeoTrip: negativi i risultati

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

Punti salienti in eBC

MonarchE - mise à jour de l'essai

How to organize a molecular tumorboards in breast…

New ADC for metastatic breast cancer?

Improvement of therapy outcome by app-based patient…

What was the most exciting news at ESMO23?

ADCs in HER2+, HER2low and TNBC - what is the future of…

Remarkable efficacies in patients with HER2+ mBC with…

Benefit for SG even after intensive pretreatment

Our guidelines are correct

ADC + Immunotherapy - the BEGONIA study paradigm

Still on track for success in HER2-low MBC

New ADC in HR+ disease

OP-1250 (Palezestrant) confirms the role of SIRDs after…

Highlights in mBC

T-DXd - new standard of care for brain mets?

Robust data from the monarchE

HS20089 - a novel ADC is coming for TNBC

OP seems to be dispensable for super responders

Fulvestran better than anastrozole, but no survival…

Patient-centered molecular medicine - a new approach

Improved oncological therapy with the smartphone

TROP2 expression as a potential mechanism of resistance…

HER2DX in the PHERgain trial

Can surgery be spared following primary systemic…

T-DXd also effective for brain metastases

Even more new generation ADCs in breast cancer?

TULIP: Trastuzumab duocarmazine without OS benefit

T-DXd in HER2+ patients with brain metastases

Abemaciclib remains consistent in 5-year follow-up

Dato-DXd - new player in advanced luminal disease

Duvalumab + Dato-DXd effective

My highlights of ESMO23 in metastatic breast cancer

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

Punti salienti in mBC

La expresión de TROP2 como potencial mecanismo de…

Lo studio BEGONIA nelle paziento con tumore triplo…

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

T-DXd - nowy standard postępowania w przerzutach do…

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust…

The optimal timing of RT after radical prostatectomy…

STAMPEDE. Bone prediction not for everyone - better…

Salvage radiotherapy the new standard

PSMA FORE: Trial and controversies

Osteoprotection at mHSPC

Brave New World in mCRPC

EMBARK - Quality of Life

EMBARK expands ENZA indication to PCa

When immunotherapy is probably not the best choice: The…

Longterm toxicity of adjuvant RT after prostatectomy

CXCR2 inhibitor in PCa

Immunotherapy in metastatic PCa

TITAN: ultra-low PSA = best prognosis

PSMAfore unleashes urooncologic opportunity

Big data and AI prediction tools

Lu-PSMA leads forward

RADICALS RT: Trial and controversies

Embark without fear

IO therapy in metastatic prostate cancer.

Negative data for pembrolizumab in mHSCPC & mCRPC

Combination of radioligand therapy with chemotherapy…

Early use of enzalutamide in advanced prostate cancer

ENZA P:Trial and controversies

CXCR2 hämmare och prostatacancer

Big Data och AI för prediktion vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor…

EMBARK och livskvalitet

STAMPEDE data. Skelettstärkande och riskstratifiering.

FGFR inhibitors and ADC combinations in urothelial…

Part 2: New standard of care in first line urothelial…

Amazing new data in bladder cancer

FGFR inhibitors: What is the best scenario for this…

Chemo-IO establishes itself in the first-line treatment…

Unique bladder delivery system of gemcitabine herolds…

DAD, DAD-IO

The FGFR story in bladder cancer at ESMO23

New SoC in firstline bladder cancer

EV + Pembro as standard of care in first-line therapy…

L'histoire du FGFR dans le cancer de la vessie à…

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Reescribiendo la historia de una enfermedad: Nuevo…

Is de-escalating therapy ready for prime-time?

Where does the future therapy go in renal cell…

Belzutifan in later lines of therapy

Kidney cancer highlights at ESMO23

Intermittent therapy also possible with TKIs

New 3rd line therapy for RCC

Belzutifan - whats next kidney cancer?

New mode of action in mRCC - ready for prime time?

Moving patients to the neoadjuvant setting in…

Circulating DNA in AEGEAN trial

Scene is set for inductive immunotherapy

ALINA - a new paradigm in operated NSCLC with…

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - immediate change of practice!

Substantial improvement in local regional NSCLC

Big improvements in early stage and a subset of…

Perioperativ immunotherapy for all resectable stage…

My highlights from ESMO 2023

Adjuvant alectinib in patients with early-stage ALK+…

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten…

Gros progrès dans les traitments medicaeux des stades…

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20…

Activating EGFR-mutation - what's coming up?

MARIPOSA: Trial and controversies

Adagrasib + pembrolizumab in patients with KRASG12C…

LIBRETO - a positive study, but was it necessary?

Amivantamab upfront? MARIPOSA trial

TROPION-Lung01: positive development

NRG fusions: a new drugable target?

MARIPOSA II: Trial and controversies

Treatment sequences for EGFR-mutated Patients

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

PAPILLON - bringing together therapy for the 1st line

Big improvements in early stage and a subset of…

Practice changing results on exon 20 insertion mNSCLC

Amivantamab as a new SoC for EGFR Exon 20…

Substantial improvement in rare alterations

Amivantamab at progression? MARIPOSA-2 trial

Does immunotherapy still have a place in EGFR-positive…

Do ADCs have brain activity?

By unanimous decision and still the champion –…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Brain metastases – options to improve the systemic…

New standard of care for metastatic EGFR exon 20…

My highlights from ESMO 2023

Heeft immunotherapie nog een plek in de behandeling van…

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Quelles séquences thérapeutiques pour les patients EGFR…

Amivantamab at progression? MARIPOSA-2 trial

Gros progrès dans les traitments medicaeux des stades…

L’amivantamab, nouveau standard de traitement pour les…

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

New hope for patients with SCLC

Tarlatamab in SCLC

Update on gynaecological cancers

Precision oncology in CUP

New data on sarkomas

New data on H&N Cancer

Evolution of the revolution - the RUBY trial

First data on luveltamab in multiline treatment for…